These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 10090432

  • 1. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
    Lipsky BA, Dorr MB, Magner DJ, Talbot GH.
    Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432
    [Abstract] [Full Text] [Related]

  • 2. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
    Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L.
    Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
    [Abstract] [Full Text] [Related]

  • 3. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
    Lipsky BA, Miller B, Schwartz R, Henry DC, Nolan T, McCabe A, Magner DJ, Talbot GH.
    Clin Ther; 1999 Apr; 21(4):675-90. PubMed ID: 10363733
    [Abstract] [Full Text] [Related]

  • 4. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
    Lipsky BA, Unowsky J, Zhang H, Townsend L, Talbot GH.
    Clin Ther; 1999 Jun; 21(6):954-65. PubMed ID: 10440620
    [Abstract] [Full Text] [Related]

  • 5. Sparfloxacin: a review.
    Schentag JJ.
    Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H, Vogel F, Elies W.
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [Abstract] [Full Text] [Related]

  • 9. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P, Mandell L, Patou G, Dankner W, Tillotson G.
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
    Henry D, Ellison W, Sullivan J, Mansfield DL, Magner DJ, Dorr MB, Talbot GH.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2262-6. PubMed ID: 9736546
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections.
    Dowzicky M, Nadler H, Dorr MB, Acusta A, Talbot GH.
    Clin Ther; 1999 May; 21(5):790-805; discussion 789. PubMed ID: 10397375
    [Abstract] [Full Text] [Related]

  • 14. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ, Meyer JM, Chuck SK, Jung R, Messick CR, Pendland SL.
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [Abstract] [Full Text] [Related]

  • 15. Sparfloxacin and levofloxacin.
    Med Lett Drugs Ther; 1997 Apr 25; 39(999):41-3. PubMed ID: 9137295
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by sinus puncture.
    Garrison N, Spector S, Buffington D, Stafford C, Granito K, Zhang H, Talbot GH.
    Ann Allergy Asthma Immunol; 2000 Jan 25; 84(1):63-71. PubMed ID: 10674567
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.
    Portier H, May T, Proust A.
    J Antimicrob Chemother; 1996 May 25; 37 Suppl A():83-91. PubMed ID: 8737128
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.
    Finch RG.
    Int J Antimicrob Agents; 1999 Jun 25; 12(1):5-17. PubMed ID: 10389642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.